Also, although there is clinical event reduction data at lower doses in diabetics, getting these data at higher doses in obesity will be very important, especially to support insurers paying a substantial part of the cost of this medication. Also important to learn, Neeland said, is that what is not known, and is not able to be known from the STEP program, are whether there are select benefits in patients with excess visceral adiposity as opposed to excess subcutaneous fat where the fat is in the body, is that related to the weight-loss response, and is it, potentially, then related to the CV benefit? Individualized interventions coupled with the right pharmacotherapy are key, though that often involves trial and error, Stanford said
Once you complete your assessment, a provider reviews your data
Researchers from the University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Churchill Hospital, Newcastle University, University of Bath, and University of Exeter also contributed to the study
doi:10.1159/000541757